Table 3 Comparison of methylated HYP2 levels and MoM values between controls and patients with preeclampsia in terms of onset time of preeclampsia.

From: Maternal total cell-free DNA in preeclampsia with and without intrauterine growth restriction

 

Controls

Preeclampsia

P†

Pa‡

Pb‡

Pc‡

EO-PE

LO-PE

2nd trimester

(n = 78)

(n = 6)

(n = 23)

    

Copies/mL

9,441

(5,878–12,251)

22,394

(14,992–38,659)

10,023

(6,356–16,374)

0.041

0.042

0.63

0.11

MoM

0.998

(0.952–1.026)

1.094

(1.057–1.140)

1.008

(0.951–1.051)

0.044

0.044

0.70

0.10

3rd trimester

(n = 58)

(n = 6)

(n = 14)

    

Copies/mL

14,969

(11,411–21,873)

72,312

(39,291–131,475)

51,918

(30,462–86,669)

 < .0001

0.001

 < .0001

0.31

MoM

0.979

(0.948–1.029)

1.103

(1.041–1.118)

1.084

(1.028–1.154)

 < .0001

0.008

 < .001

0.96

  1. Data are given as median (interquartile range).
  2. Pa, EO-PE versus controls; Pb, LO-PE versus controls; Pc, EO-PE versus LO-PE.
  3. EO-PE early-onset preeclampsia, LO-PE late-onset preeclampsia, MoM multiple of the median.
  4. †P value by the Kruskal–Wallis test.
  5. ‡P value by the Wilcoxon rank sum test (adjusted by using the step-up Bonferroni method).
Back to article page